Patents by Inventor Han Suk RYU

Han Suk RYU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers
    Patent number: 11939334
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: March 26, 2024
    Assignee: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers
    Patent number: 11912710
    Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: February 27, 2024
    Assignee: UPPTHERA, INC.
    Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
  • A Method for Predicting Prognosis of Cancer and the Composition Thereof
    Publication number: 20220267855
    Abstract: The present disclosure relates to a method for predicting prognosis of cancer and a composition thereof. More specifically, the present disclosure relates to a composition and a method for predicting prognosis of breast cancer and predicting the treatment effect of chemotherapy. The present disclosure provides gene expression information useful for predicting whether a cancer patient is more likely to respond favorably to treatment in chemotherapy.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 25, 2022
    Inventors: Won Shik Han, Han Byoel Lee, In Ae Park, Han Suk Ryu, Sei Hyun Ahn, Jong Won Lee, Sae Byul Lee, Hee Jin Lee, Ae Ree Kim, Chung Yeul Kim, Sung Roh Yoon, Sun Kim, Sun Young Kwon, Min Su Kim, Jeong Hee Jo
  • METHOD OF QUANTIFYING HER2 IN BREAST CANCER SAMPLE BY MASS SPECTROMETRY AND SCORING HER2 STATUS USING THE SAME
    Publication number: 20220221460
    Abstract: Provided is a method for accurate quantification of a HER2 protein in a breast cancer tissue sample by mass spectrometry and a HER2 scoring based thereon. A method according to the presently claimed subject matter is accurate and can make reproducible measurement compared to conventional methods. If possible, personalized therapy according to the method of the presently claimed subject matter can prolong lives of the patients and exceptionally reduce the socioeconomic cost nationwide.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 14, 2022
    Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Youngsoo KIM, Han Suk RYU, Hyunsoo KIM, Misol DO